Lead Product(s) : Tiprelestat
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : National Institutes of Health
Deal Size : Undisclosed
Deal Type : Funding
Stanford University Secures NIH Grant to Advance Tiakis Biotech´s Elafin
Details : The net proceeds will be used to fund a U.S. Phase II trial of Elafin (tiprelestat) for the treatment of Pulmonary Arterial Hypertension (PAH).
Product Name : Elafin
Product Type : Protein
Upfront Cash : Undisclosed
September 08, 2025
Lead Product(s) : Tiprelestat
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : National Institutes of Health
Deal Size : Undisclosed
Deal Type : Funding
Lead Product(s) : Tiprelestat
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Duke University | SRI International | National Heart, Lung, and Blood Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Subcutaneous Elafin in Healthy Subjects
Details : Elafin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pulmonary Arterial Hypertension.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
May 14, 2018
Lead Product(s) : Tiprelestat
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Duke University | SRI International | National Heart, Lung, and Blood Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
